EUVIMEDEUVIMED entdecken
Übersichtsarbeit

News at XI: moving beyond factor Xa inhibitors

James C Fredenburgh, Jeffrey I Weitz

Journal of Thrombosis and Haemostasis · 2023

DOI: 10.1016/j.jtha.2023.04.021 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Thrombosis and Haemostasis, 2023. Verfasst von James C Fredenburgh und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamil…. Hauptthemen laut MEDLINE: Anticoagulants, Factor Xa Inhibitors. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: CIHR, Heart and Stroke Foundation of Canada, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oral anticoagulants are a mainstay for the prevention and treatment of arterial and venous thrombosis. Direct oral anticoagulants (DOACs) have replaced vitamin K antagonists for many indications. Currently available DOACs include dabigatran, which inhibits thrombin, and apixaban, edoxaban, and rivaroxaban, which inhibit factor (F) Xa. A new class of DOACs is under development. These new DOACs, which include asundexian and milvexian, inhibit FXIa, which is positioned in the intrinsic pathway of coagulation. Anticoagulants that target FXIa have the potential to be safer than the current DOACs because there is emerging evidence that FXI is essential for thrombosis but mostly dispensable for hemostasis. In addition to the oral inhibitors of FXIa, parenteral inhibitors are also under development. These include fesomersen, an antisense oligonucleotide that reduces the hepatic synthesis of FXI; abelacimab, an antibody that binds to FXI and blocks its activation; and osocimab, an FXIa inhibitory antibody. Focusing on these new agents, this article describes the unmet needs in oral anticoagulation therapy, explains why FXI is a promising target for new oral anticoagulants, reviews phase 2 clinical data on new agents, describes ongoing phase 3 trials, and provides a perspective on the opportunities and challenges for FXI inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsFactor Xa InhibitorsHumansAdministration, OralDabigatranFactor XIRivaroxabanPyrimidinesTriazoles

Stichwörter der Autor:innen

anticoagulantcoagulationfactor XIthromboembolismthrombosis

Substanzen

AnticoagulantsDabigatranFactor Xa InhibitorsFactor XIRivaroxabanmilvexianPyrimidinesTriazoles

Autor:innen und Institutionen

  • Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada.
  • Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada; Department of Biochemistry and Biomedical Scienc…

Förderung

  • CIHR
  • Heart and Stroke Foundation of Canada
  • Canadian Institutes of Health Research

Zitieren

APA

Fredenburgh, J. C., & Weitz, J. I. (2023). News at XI: moving beyond factor Xa inhibitors. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2023.04.021

Vancouver

Fredenburgh JC, Weitz JI. News at XI: moving beyond factor Xa inhibitors. Journal of Thrombosis and Haemostasis. 2023. doi:10.1016/j.jtha.2023.04.021

BibTeX
@article{Fredenburgh2023,
  author = {Fredenburgh, James C and Weitz, Jeffrey I},
  title = {News at XI: moving beyond factor Xa inhibitors},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2023},
  doi = {10.1016/j.jtha.2023.04.021}
}
Kostenlos starten →